Residual disease is cancer that remains after a treatment.
Patients with liquid tumors have benefited from a series of technical revolutions in residual disease detection.
But patients with solid tumors like breast cancer have been left behind. Until now.
Scientists, we need your help! Our team was selected by the NIH RADx initiative  to scale national COVID testing. Our project supports hospitals and clinical labs that run nucleic acid tests. Our mandate is to increase the number of SARS CoV-2 tests from ~0.5M per day to +5M per day by mid-September, before the influenza pandemic hits in the fall. This is an ambitious $30M+ public-private partnership with few historical precedents.
Scientists from academia, industry and the government are taking leaves of absence to support this effort. Some plan to stay onboard as we advance to Phase 2, while others will return to their day jobs after we submit to FDA. If you want to help, but don’t know how to manage your current roles, reach out and we’ll find a way to make it work. Unprecedented challenges require an unprecedented scientific response.
You can reach us at firstname.lastname@example.org
 930 Brittan Ave, San Carlos. https://mbcbiolabs.com/facilities-sf-sc/